You are here

New Adjuvant Treatment for HER2-positive Early Breast Cancer

Kadcyla Cut Risk of Recurring Disease by Half Compared to Herceptin

Trastuzumab emtansine (Kadcyla®, Roche) has received FDA approval for adjuvant treatment of HER2-positive early breast cancer (eBC) in people with residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.

The FDA rapidly reviewed and approved the application under the agency’s Real-Time Oncology Review and the Assessment Aid pilot programs, which led to an approval in just over 12 weeks.

The approval is based on results from the phase 3 KATHERINE study, an international, multicenter, two-arm, randomized, open-label trial showing that trastuzumab emtansine significantly reduced the risk of invasive breast cancer recurrence or death from any cause by 50% compared to Herceptin (Genentech), as an adjuvant treatment in people with HER2-positive eBC who have residual invasive disease after neoadjuvant taxane and Herceptin-based treatment. 

At three years, 88.3% of people treated with trastuzumab emtansine did not have a recurrence of breast cancer compared to 77.0% treated with Herceptin, an improvement of 11.3%.

The most common side effects were fatigue; nausea; increased blood levels of liver enzymes; musculoskeletal pain; bleeding; decreased platelet count; headache; numbness, tingling or pain in the hands or feet; and joint pain.

Trastuzumab emtansine is an antibody-drug conjugate (ADC) designed to deliver powerful chemotherapy directly to HER2-positive cancer cells, which could restrict damage to healthy tissue. The drug combines two anti-cancer properties joined by a stable linker: trastuzumab’s HER2-targeting properties and the chemotherapy agent DM1.

Source: Roche, May 6, 2019

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs